BCYC
BEARISH
$6.95
Live
Bicycle Therapeutics plc · NASDAQ
Target $21.5
(+209.4%)
$6.03
52W Range
$13.63
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$482.11M
P/E
N/A
ROE
-34.6%
Profit margin
N/A
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
68%
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a remarkable 338.5% year-over-year revenue growth and strong analyst target price of $21.50 implying 210% upside, the company continues to report deep operating losses (-558.64% operating margin), deteriorating earnings (YoY EPS growth of -18.1%), and inconsistent earnings surprises, with only 1 out of the last 4 quarters beating estimates. High valuation multiples (Price/Sales of 17.01) contrast with negative profitability and weak insider sentiment, while recent insider selling adds downward pressure. Although the balance sheet appears strong with a current ratio of 10.66 and minimal debt, the lack of profitability and cash flow transparency limits confidence in sustainable recovery.
Key Strengths
Exceptional year-over-year revenue growth of 338.50% suggests strong commercial or partnership momentum
Exceptionally strong liquidity position with current ratio of 10.66 and quick ratio of 10.33
Very low leverage with Debt/Equity ratio of just 0.01, reducing financial risk
Analyst consensus supports strong upside with a $21.50 target price, implying over 200% potential return
Recent weekly price performance shows positive momentum (+6.8%) amid broader negative trends
Key Risks
Piotroski F-Score of 4 indicates weak financial health and limited operational strength
Operating margin of -558.64% reflects severe unprofitability and cost inefficiency
Negative ROE (-34.59%) and negative ROA (-20.59%) demonstrate poor capital utilization
Insider selling activity in the last 6 months signals lack of confidence from corporate insiders
Forward P/E of -1.99 and negative earnings trend indicate no near-term profitability
AI Fair Value Estimate
Based on comprehensive analysis
$21.5
+209.4% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
30
65
38
45
0
AI Verdict
High-risk speculative biotech with unproven profitability despite revenue surge
Key drivers: High revenue growth, Negative earnings trend, Weak Piotroski score, Bullish analyst target, Bearish insider activity
Confidence
70%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Book ratio of 0.78 suggests possible asset-based floor
Watchpoints
- Price/Sales of 17.01 is extremely high for unprofitable company
- Forward P/E of -1.99 indicates no earnings support for valuation
- No Graham Number due to unprofitability
Future
65/100
Ref Growth rates
Positives
- 338.50% YoY revenue growth is exceptional
- Analyst target implies strong future expectations
Watchpoints
- Earnings growth YoY is negative (-18.1%)
- Forward P/E negative, signaling no profitability in near term
Past
38/100
Ref Historical trends
Positives
- Some quarters showed strong earnings beats (e.g., +48.7% in Q2 2024)
Watchpoints
- Only 1 of last 4 quarters beat estimates
- History of large earnings misses (e.g., -101.6% in Q1 2021)
- Long-term price performance deeply negative (5Y change: -74.2%)
Health
45/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current and quick ratios are exceptionally high (10.66 and 10.33)
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- No Altman Z-Score available for distress risk assessment
- Operating and net margins deeply negative
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend program (yield N/A)
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$6.95
Analyst Target
$21.5
Upside/Downside
+209.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BCYC and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics plc
Primary
|
-74.2% | -74.7% | -47.5% | -20.1% | -0.6% | +6.8% |
|
ADCT
ADC Therapeutics SA
Peer
|
-86.0% | +85.4% | +181.5% | -5.0% | -9.1% | -4.3% |
|
DNA
Ginkgo Bioworks Holdings, Inc.
Peer
|
-98.1% | -83.7% | 0.0% | -42.0% | +6.9% | -2.0% |
|
RGNX
REGENXBIO Inc.
Peer
|
-72.0% | -49.8% | +59.8% | -19.1% | +14.6% | +7.8% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-27.7% | +432.4% | +47.8% | -20.4% | +5.2% | -4.7% |
BCY
Bicycle Therapeutics plc
Primary
5Y
-74.2%
3Y
-74.7%
1Y
-47.5%
6M
-20.1%
1M
-0.6%
1W
+6.8%
ADC
ADC Therapeutics SA
Peer
5Y
-86.0%
3Y
+85.4%
1Y
+181.5%
6M
-5.0%
1M
-9.1%
1W
-4.3%
DNA
Ginkgo Bioworks Holdings, Inc.
Peer
5Y
-98.1%
3Y
-83.7%
1Y
0.0%
6M
-42.0%
1M
+6.9%
1W
-2.0%
RGN
REGENXBIO Inc.
Peer
5Y
-72.0%
3Y
-49.8%
1Y
+59.8%
6M
-19.1%
1M
+14.6%
1W
+7.8%
AQS
Aquestive Therapeutics, Inc.
Peer
5Y
-27.7%
3Y
+432.4%
1Y
+47.8%
6M
-20.4%
1M
+5.2%
1W
-4.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.99
PEG Ratio
N/A
P/B Ratio
0.78
P/S Ratio
17.01
EV/Revenue
-5.66
EV/EBITDA
0.57
Market Cap
$482.11M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-558.64%
Gross Margin
N/A
ROE
-34.59%
ROA
-20.59%
Growth
Revenue and earnings growth rates
Revenue Growth
+338.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
10.66
Strong
Quick Ratio
10.33
Excellent
Cash/Share
$9.35
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-24
$N/A
2025-10-30
$-0.85
+20.4% surprise
2025-08-08
$-1.14
-22.0% surprise
2025-05-01
$-0.88
-8.8% surprise
Healthcare Sector Comparison
Comparing BCYC against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-34.59%
This Stock
vs
-88.14%
Sector Avg
-60.8%
(Below Avg)
Debt to Equity
0.01
This Stock
vs
2.66
Sector Avg
-99.7%
(Less Debt)
Revenue Growth
338.5%
This Stock
vs
124.04%
Sector Avg
+172.9%
(Fast Growth)
Current Ratio
10.66
This Stock
vs
4.47
Sector Avg
+138.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics plc
|
BEARISH | $482.11M | - | -34.6% | -% | $6.95 | |
|
ADCT
ADC Therapeutics SA
|
NEUTRAL | $482.77M | - | -% | -175.3% | $3.8 | Compare |
|
DNA
Ginkgo Bioworks Holdings, Inc.
|
BEARISH | $487.34M | - | -51.1% | -183.8% | $7.87 | Compare |
|
RGNX
REGENXBIO Inc.
|
BEARISH | $489.85M | - | -107.0% | -113.8% | $9.49 | Compare |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $490.45M | - | -% | -188.1% | $4.02 | Compare |
BCYC
Bicycle Therapeutics plc
BEARISH
Mkt Cap
$482M
P/E
-
ROE
-34.6%
Price
$6.95
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award | 38,000 | - |
| 2026-01-02 | HOPPENOT HERVE | Director | Stock Award | 3,032 | - |
| 2025-10-03 | HANNAY MICHAEL CHARLES FERGUSON | Officer | Sale | 723 | $6,076 |
| 2025-10-02 | YOUNG ALETHIA R. | Chief Financial Officer | Sale | 482 | $4,103 |
| 2025-10-02 | SWANTON ROBERT CHARLES | Director | Sale | 102 | $872 |
BAKER BROS ADVISORS L.P.
Beneficial Owner of more than 10% of a Class of Security
2026-01-02
38,000 shares
HOPPENOT HERVE
Director
2026-01-02
3,032 shares
HANNAY MICHAEL CHARLES FERGUSON
Officer
2025-10-03
723 shares
·
$6,076
YOUNG ALETHIA R.
Chief Financial Officer
2025-10-02
482 shares
·
$4,103
SWANTON ROBERT CHARLES
Director
2025-10-02
102 shares
·
$872
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
10 analysts
Truist Securities
2025-11-24
Hold
Citizens
2025-10-31
Market Outperform
Market Outperform
RBC Capital
2025-10-31
Outperform
Sector Perform
JMP Securities
2025-08-12
Market Outperform
Market Outperform
Morgan Stanley
2025-08-12
Equal-Weight
Equal-Weight
Oppenheimer
2025-08-11
Outperform
Outperform
Past News Coverage
Recent headlines mentioning BCYC from our newsroom.
Newest → oldest
No matching news yet.